Cargando…

Characterization of receptor tyrosine kinase activation and biological activity of toceranib phosphate in canine urothelial carcinoma cell lines

BACKGROUND: Urothelial carcinoma (UC) accounts for > 90% of canine tumors occurring in the urinary bladder. Toceranib phosphate (TOC) is a multi-target receptor tyrosine kinase (RTK) inhibitor that exhibits activity against members of the split kinase family of RTKs. The purpose of this study was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Korec, Daniela I., Louke, Darian S., Breitbach, Justin T., Geisler, Jennifer A., Husbands, Brian D., Fenger, Joelle M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487586/ https://www.ncbi.nlm.nih.gov/pubmed/34600548 http://dx.doi.org/10.1186/s12917-021-03027-0

Ejemplares similares

The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines
por: Breitbach, Justin T., et al.
Publicado: (2021)

Characterization of WWOX expression and function in canine mast cell tumors and malignant mast cell lines
por: Makii, Rebecca, et al.
Publicado: (2020)

Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma
por: Musser, Margaret L., et al.
Publicado: (2021)

Toceranib phosphate in the management of canine insulinoma: A retrospective multicentre study of 30 cases (2009–2019)
por: Sheppard‐Olivares, Sabina, et al.
Publicado: (2022)

Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor
por: Halsey, Charles HC, et al.
Publicado: (2014)

Plasma cytokeratin‐18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib
por: Kovac, Rachel L., et al.
Publicado: (2018)

A Multi-Institutional Retrospective Analysis of Toceranib Phosphate for Presumed or Confirmed Canine Aortic Body Chemodectomas
por: Coto, Giovanna M., et al.
Publicado: (2021)

Plasma Cytokeratin 18 and fecal Alpha‐1 Antitrypsin concentrations in dogs with osteosarcoma receiving carboplatin chemotherapy
por: Taikowski, Kathryn, et al.
Publicado: (2020)

Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs
por: Tjostheim, S.S., et al.
Publicado: (2016)

Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs
por: YAMAZAKI, Hiroki, et al.
Publicado: (2017)

Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017)
por: Musser, Margaret L., et al.
Publicado: (2018)

Transcriptome of Two Canine Prostate Cancer Cells Treated With Toceranib Phosphate Reveals Distinct Antitumor Profiles Associated With the PDGFR Pathway
por: Kobayashi, Priscila E., et al.
Publicado: (2020)

Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma
por: Gardner, Heather L., et al.
Publicado: (2015)

A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma
por: Rippy, Sarah B., et al.
Publicado: (2016)

Effects of Toceranib Phosphate on the Hypothalamic‐Pituitary‐Thyroid Axis in Tumor‐Bearing Dogs
por: Hume, K.R., et al.
Publicado: (2017)

Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs
por: Yamazaki, Hiroki, et al.
Publicado: (2020)

Toceranib phosphate-associated nephrotic syndrome in a dog: a case report
por: Remerowski, Shannon M., et al.
Publicado: (2021)

Erratum to: A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma
por: Rippy, Sarah B., et al.
Publicado: (2016)

Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs
por: Berger, Erika P., et al.
Publicado: (2018)

Toceranib phosphate and firocoxib-mediated partial response in a dog with advanced intranasal sarcoma
por: OSADA, Hironari, et al.
Publicado: (2023)

Toceranib phosphate (Palladia) reverses type 1 diabetes by preserving islet function in mice
por: KISHI, Kazuhisa, et al.
Publicado: (2023)

Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
por: Regan, Daniel P., et al.
Publicado: (2022)

Pulse‐Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs
por: Burton, J.H., et al.
Publicado: (2015)

Long-term survival in a cat with pancreatic adenocarcinoma treated with surgical resection and toceranib phosphate
por: Todd, Johanna E, et al.
Publicado: (2020)

Long-term survival in a dog with primary hepatic neuroendocrine tumor treated with toceranib phosphate
por: ICHIMATA, Masanao, et al.
Publicado: (2021)

Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs
por: Olsen, Jaime A., et al.
Publicado: (2018)

Novel Tyrosine Kinase Targets in Urothelial Carcinoma
por: Torres-Jiménez, Javier, et al.
Publicado: (2021)

Effects of Tyrosine Kinase Inhibitor-masitinib Mesylate on Canine Mammary Tumour Cell Lines
por: Ustun-Alkan, Fulya, et al.
Publicado: (2021)

Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose
por: Bernabe, Luis Feo, et al.
Publicado: (2013)

Feline restrictive orbital myofibroblastic sarcoma treated with toceranib phosphate (Palladia) as adjuvant chemotherapy: A case study of one cat
por: Komatsu, Hiroyuki, et al.
Publicado: (2023)

Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder
por: Lee, Young H., et al.
Publicado: (2021)

MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines
por: Lopez, Cecilia M., et al.
Publicado: (2018)

Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs
por: Heaton, Caitlin M., et al.
Publicado: (2020)

Palmar–plantar erythrodysesthesia syndrome resulting from toceranib phosphate in a dog with apocrine gland anal sac adenocarcinoma: a case report
por: Kim, Eunjoo, et al.
Publicado: (2023)

Activating Mutation in the Receptor Tyrosine Kinase FLT3 with Clinicopathological Relevance in Canine Mast Cell Tumors
por: Manachai, Nawin, et al.
Publicado: (2022)

Canine pulmonary adenocarcinoma tyrosine kinase receptor expression and phosphorylation
por: Mariotti, Evan T, et al.
Publicado: (2014)

A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis
por: Tani, Hiroyuki, et al.
Publicado: (2021)

Characterizing the metabolic role of STAT3 in canine osteosarcoma
por: Gardner, Heather L., et al.
Publicado: (2022)

Tyrosine kinase inhibitors as an alternative treatment in canine mast cell tumor
por: Coelho, Yasmin Nascimento Bernardes, et al.
Publicado: (2023)

A cultured approach to canine urothelial carcinoma: molecular characterization of five cell lines
por: Shapiro, SG, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pglel04m9ogk1ilor82kmrb124